-
Capital, M&A & Industry Strategy3 days agoTyra shares slip as bladder cancer responses fall short of investor expectations
Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.
-
Capital, M&A & Industry Strategy3 days agoA booming business on Wall Street would love more biotechs to quietly die
Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.
-
Capital, M&A & Industry Strategy3 days agoNovartis shareholder calls for board overhaul following costly deal setbacks: Reuters
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
-
Capital, M&A & Industry Strategy3 days agoSolstice Oncology secures $225m to drive porustobart’s development for cancer
The financing was raised in a Series A round led by RA Capital Management, with participation from Forbion, Canaan Partners and other investors. Porustobart is a...
-
Capital, M&A & Industry Strategy3 days agoNICE says no to Gilead’s lenacapavir for HIV PrEP
NICE's decision not to recommend NHS funding of Gilead's twice-yearly injectable for prevention of HIV has drawn fierce criticism from charities.
-
Capital, M&A & Industry Strategy3 days agoTwoStep Therapeutics secures $62.5m funding to advance TS-104
Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA,...
-
Capital, M&A & Industry Strategy3 days agoAugust biopharma layoffs impact just over 500, down 90% year over year
Last month, biotech and pharma companies making or planning workforce cuts included three whose reductions will more than halve their workforces. Blueprint Medicines’ layoffs will affect...
-
Capital, M&A & Industry Strategy4 days agoOver-The-Counter Monograph Drug User Fee Program (OMUFA)
A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potential funding mechanism to supplement congressional non user-fee appropriations.
-
Capital, M&A & Industry Strategy4 days ago2026 IPO stock tracker: How newly public biotechs are performing
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
-
Capital, M&A & Industry Strategy4 days ago
Luma locks down 15-year, $410M fund for life science investments
Luma Group announced the final close of its inaugural life sciences venture capital fund totaling $410 million.
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
